Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 39Unknown 11Terminated 11Recruiting 5Active not recruiting 3Withdrawn 2Suspended 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 4Genitourinary 3Dermatologic 3Head & Neck 2Breast 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Renal Cell 3Kidney Neoplasms 1

Interventions

pembrolizumab 65Nivolumab 58Magnetic Resonance Spectroscopy 53enzalutamide 39Abiraterone Acetate 37Radiosurgery 36Gemcitabine 35Specimen Handling 32Radiotherapy 32Ipilimumab 32Androgen Antagonists 32Prednisone 31apalutamide 28Cisplatin 28Docetaxel 27Leuprolide 26atezolizumab 25Carboplatin 25durvalumab 23cabozantinib 23darolutamide 20acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 19olaparib 18Goserelin 17Radiation 16Gonadotropin-Releasing Hormone 16Biopsy 16gallium 68 PSMA-11 15Pluvicto 15avelumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × aldesleukin × Genitourinary × Clear all
NCT01038778 2026-04-13

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
47 enrolled 15 charts
Genitourinary

Carcinoma, Renal Cell

NCT02306954 2025-03-10

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Providence Health & Services

Phase 2 Active not recruiting
84 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03501381 2023-09-01

High Dose IL 2 and Entinostat in RCC

Hoosier Cancer Research Network

Phase 2 Active not recruiting
46 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡